Change Language

Select Language

Indian Vaccine Market to Grow at 13.4% During 2022-2027, Impelled by Rising Prevalence of Life-Threatening Diseases

Published on Sep 22, 2017

According to the latest report by IMARC Group, titled "Indian Vaccine Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027," the Indian vaccine market grow at a CAGR of 13.4% during 2022-2027. Vaccine refers to a medicine that aids in protecting against harmful diseases. It utilizes the body’s natural defenses in order to build resistance to infections while making the immune system stronger. It recognizes the invading foreign substance, such as the virus or bacteria, and produces antibodies that act as a barrier to prevent the infections. It is widely available in different forms, such as liquids, injection shots, nasal sprays and pills that defend the body against bacteria and viruses. Some of the commonly utilized vaccines include live-attenuated, inactivated, subunit, recombinant, polysaccharide, and conjugate, toxoid, messenger ribonucleic acid (mRNA) and viral vector vaccines.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Indian VaccineMarket Trends:

The Indian market is primarily driven by significant growth in the pharmaceutical industry. Along with this, the increasing investments by private and public firms for improving the overall pharmaceutical infrastructure is creating a positive market outlook. Moreover, the growing prevalence of life-threatening diseases, such as the rapid outbreak of coronavirus disease (COVID-19), has provided a boost to the demand for vaccines across the country. Additionally, numerous initiatives undertaken by the government of India to administer vaccines torural and underserved areas are impacting the market growth favorably. Furthermore, extensive research and development (R&D) activities conducted by key players for vaccine development, are supporting the Indian vaccine industry to grow significantly. The market is further driven by continual technological advancements in production processes and the advent of improved cold storage facilities.Other factors, including continuous improvements in the healthcare sector, the rising awareness among the masses, low cost of production, continual developments in the supply chain and distribution channels, and the increasing number of research laboratories and clinical centers, are also positively influencing the market across India.

Market Summary:

  • The market has been analyzed on the basis of various monovalent and combined vaccines into Bacillus Calmette–Guérin (BCG), Haemophilus influenzae type b (Hib), Influenza, Varicella, Typhoid, Japanese Encephalitis, Measles, Tetanus Toxoid, Hepatitis A, Rubella, Diphtheria, Tetanus and Pertussis (DPT), Oral Polio Vaccine (OPV), Measles, Mumps and Rubella (MMR), Rotavirus, Hepatitis B, Pneumococcal, Meningococcal, Rabies, Human Papillomavirus (HPV), Hexavalent and Dengue vaccines.
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of these players include GlaxoSmithKline, Sanofi Aventis, Serum Institute of India, Panacea Biotec, Pfizer, Novartis, VHB Lifesciences, Zydus Cadila and MSD.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us


Tel: +1-631-791-1145
Follow us on twitter: @imarcglobal


Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91-120-433-0800 )

Drop us an email at